🎯 Bottom Line Up Front
From an insurance standpoint, bronchiectasis represents moderate to high mortality risk depending on severity, with particular concern about progressive respiratory failure, recurrent severe infections, and cardiovascular complications from chronic lung disease. However, many individuals with mild bronchiectasis maintain stable disease for years or decades with appropriate management.
This guide explains how insurance companies assess bronchiectasis, what documentation maximizes your approval chances, which carriers offer the most competitive rates for pulmonary conditions, and strategies to secure the best possible coverage despite this chronic respiratory disease.
U.S. adults diagnosed with bronchiectasis
Typical rating for mild, stable cases
Optimal stability period before applying
Pulmonary function threshold for best rates
Understanding How Insurers Evaluate Bronchiectasis
Key insight: Life insurance underwriters focus on disease severity markers—particularly exacerbation frequency, pulmonary function decline rate, and complications—rather than the diagnosis alone.
Bronchiectasis underwriting is complex because the condition encompasses a wide spectrum from nearly asymptomatic disease to severe, life-limiting respiratory failure. Insurers must differentiate between these vastly different prognoses to appropriately assess risk.
Key Underwriting Factors
When evaluating bronchiectasis applications, underwriters systematically analyze multiple disease severity indicators:
- Exacerbation frequency: Number of acute worsening episodes per year requiring antibiotics or hospitalization
- Pulmonary function: FEV1, FVC, and rate of decline over time
- Disease extent: Number of lung lobes affected on CT imaging
- Underlying etiology: Cystic fibrosis (very high risk) versus post-infectious (more favorable)
- Chronic colonization: Presence of Pseudomonas aeruginosa or other resistant organisms
- Hemoptysis history: Frequency and severity of blood in sputum
- Oxygen requirement: Need for supplemental oxygen at rest or with exertion
- Exercise tolerance: Functional capacity and limitations
- Complications: Respiratory failure, cor pulmonale, massive hemoptysis
- Treatment intensity: Daily antibiotics, nebulized medications, airway clearance requirements
Favorable Underwriting Profile
- Mild bronchiectasis (1-2 lobes)
- 0-1 exacerbations annually
- FEV1 >70% predicted
- No hospitalizations in 2+ years
- No oxygen requirement
- No hemoptysis episodes
- No Pseudomonas colonization
Expected Outcome: Standard to Table 4
Moderate Underwriting Profile
- Moderate disease (3-4 lobes)
- 2-4 exacerbations annually
- FEV1 50-70% predicted
- Occasional hospitalization
- Exertional oxygen may be needed
- Minor hemoptysis episodes
- Pseudomonas colonization possible
Expected Outcome: Table 4-8
Unfavorable Underwriting Profile
- Severe disease (5+ lobes)
- 5+ exacerbations annually
- FEV1 <50% predicted
- Frequent hospitalizations
- Continuous oxygen required
- Massive hemoptysis history
- Respiratory failure episodes
Expected Outcome: Postponement or decline
Professional Insight
“Bronchiectasis underwriting requires nuanced understanding of disease trajectory. We’ve successfully secured standard-rated policies for clients with mild, localized disease who demonstrate years of stability, while even moderate cases typically require creative carrier selection and realistic expectation setting. The most critical conversation involves timing—applying during a stable period after comprehensive pulmonary evaluation versus waiting if disease control has recently changed or testing is outdated.”
– InsuranceBrokers USA – Management Team
For more insights on how various medical conditions affect coverage decisions, see our comprehensive guide on Life Insurance Approvals with Pre-Existing Medical Conditions.
Severity Classification and Its Impact on Rates
Key insight: Bronchiectasis severity—determined by exacerbation frequency, lung function, and disease extent—is the single most important factor in determining insurability and premium costs.
Underwriters categorize bronchiectasis severity using clinical criteria that correlate with mortality risk. Understanding where you fall on this spectrum helps set realistic expectations for coverage options.
Clinical Severity Classifications
Multiple severity scoring systems exist (BSI, FACED, E-FACED), but insurance underwriters focus on practical clinical markers:
Mild Bronchiectasis
Mild Disease Characteristics
Clinical Features:
- Limited anatomic involvement (1-2 lung lobes)
- 0-2 exacerbations per year requiring oral antibiotics
- No hospitalizations for respiratory causes in past 2+ years
- FEV1 ≥70% of predicted value
- No chronic bacterial colonization or only commensal organisms
- Minimal daily symptoms (occasional morning cough)
- No supplemental oxygen requirement
- Maintains regular activities without significant limitation
Underwriting Implications:
- May qualify for Standard rates if extremely stable with FEV1 >80%
- Typically receives Standard with Table 2-4 rating
- Requires comprehensive pulmonary workup demonstrating stability
- Need 12-24 months of documented stable course
- Post-infectious etiology viewed more favorably than congenital/genetic causes
Typical Premium Impact: 50-100% above standard rates
Moderate Bronchiectasis
Moderate Disease Characteristics
Clinical Features:
- Moderate anatomic involvement (3-4 lung lobes)
- 3-5 exacerbations per year, some requiring IV antibiotics
- Occasional hospitalization (1-2 times in past 2 years)
- FEV1 50-69% of predicted value
- May have chronic Pseudomonas or other pathogen colonization
- Daily productive cough with moderate sputum production
- May require supplemental oxygen with exertion
- Some limitation of activities and exercise tolerance
Underwriting Implications:
- Typically receives Table 4-8 ratings
- Requires extensive pulmonary documentation
- Hospitalization frequency closely scrutinized
- Need evidence that disease is not rapidly progressing
- Carrier selection critical—many will postpone or decline
Typical Premium Impact: 100-200% above standard rates
Severe Bronchiectasis
Severe Disease Characteristics
Clinical Features:
- Extensive anatomic involvement (5-6 lung lobes, diffuse disease)
- Frequent exacerbations (5+ per year) requiring repeated IV antibiotics
- Multiple hospitalizations (3+ in past year)
- FEV1 <50% of predicted value
- Chronic colonization with resistant organisms (Pseudomonas, MRSA, NTM)
- Continuous daily symptoms with large volume sputum production
- Requires continuous supplemental oxygen
- Significant functional limitation, reduced quality of life
- Complications: cor pulmonale, respiratory failure, massive hemoptysis
Underwriting Implications:
- Most carriers will postpone or decline traditional coverage
- May qualify for Table 10+ with specialty carriers if stable
- Consider guaranteed issue or graded benefit policies
- High likelihood of claim within policy contestability period
Typical Outcome: Postponement, decline, or guaranteed issue products only
Exacerbation Frequency: The Critical Metric
Exacerbation rate is one of the strongest predictors of mortality in bronchiectasis and receives intense underwriting scrutiny:
| Annual Exacerbation Rate | Hospitalization Pattern | Typical Rate Classification | Additional Requirements |
|---|---|---|---|
| 0-1 per year | No hospitalizations | Standard to Table 4 | Stable PFTs, no complications |
| 2-3 per year | Rare hospitalization (>12 months ago) | Table 2-6 | FEV1 >60%, good functional status |
| 4-5 per year | Occasional hospitalization (1-2/year) | Table 6-10 | Must show stability, no rapid decline |
| 6+ per year | Frequent hospitalizations (3+/year) | Postponement or decline | Consider alternative products |
Professional Insight
“Exacerbation history is where we spend most of our time with bronchiectasis clients. A single hospitalization three years ago has minimal impact, but three hospitalizations in the past year dramatically changes the underwriting picture. We work closely with clients to document not just the raw numbers but the trajectory—are exacerbations becoming more or less frequent? Are they responding well to treatment? This context can mean the difference between Table 4 and postponement.”
– InsuranceBrokers USA – Management Team
The Underwriting Process for Chronic Lung Disease
Key insight: Bronchiectasis underwriting requires comprehensive pulmonary evaluation documentation, detailed treatment history, and clear evidence of disease stability or slow progression.
When you apply for life insurance with bronchiectasis, expect an intensive medical review focused on establishing your precise disease severity and prognosis.
Application Questions About Bronchiectasis
Life insurance applications include extensive respiratory disease questions:
- Date of bronchiectasis diagnosis and how it was discovered
- Underlying cause or precipitating factors (cystic fibrosis, immune deficiency, prior infection)
- Number of lung lobes affected and disease distribution
- Number of respiratory exacerbations in past 12 months and past 24 months
- Number of hospitalizations for respiratory causes in past 2-5 years
- Emergency room visits for breathing difficulties
- Current respiratory symptoms (cough, sputum production, shortness of breath, wheezing)
- Hemoptysis (blood in sputum) episodes—frequency and severity
- Supplemental oxygen use (continuous, exertional, nocturnal, or none)
- Current medications (antibiotics, bronchodilators, mucolytics, anti-inflammatories)
- Airway clearance techniques (chest physiotherapy, devices, nebulizers)
- Pulmonary function test results and dates
- Recent chest CT or X-ray findings
- Complications (respiratory failure, cor pulmonale, pneumothorax)
- Smoking history (current, past, never)
Medical Records Underwriters Request
Expect comprehensive records from multiple specialists:
| Record Source | Information Extracted | Underwriting Importance |
|---|---|---|
| Pulmonologist Notes | Diagnosis details, severity assessment, treatment plans, exacerbation management | Very High – specialist expertise critical |
| Pulmonary Function Tests | FEV1, FVC, DLCO values and trends over time | Very High – objective disease severity measure |
| Chest CT Scans | Extent of bronchiectasis, number of lobes affected, severity of changes | High – anatomic disease burden assessment |
| Hospital Records | Admission frequency, length of stay, treatments required, complications | Very High – indicates severe exacerbations |
| Primary Care Records | Overall health context, comorbidities, frequency of acute visits | Moderate – comprehensive health picture |
| Sputum Culture Results | Bacterial colonization, antibiotic resistance patterns | Moderate to High – Pseudomonas significant |
| Emergency Room Visits | Acute respiratory distress episodes, interventions needed | High – suggests inadequate control |
⚠️ Underwriting Red Flags
Certain findings significantly worsen insurability prospects:
- Rapidly declining FEV1: Loss of >3-5% lung function annually indicates progressive disease
- Cystic fibrosis etiology: Even mild CF-related bronchiectasis carries high mortality risk
- Frequent hospitalizations: Three or more respiratory admissions in past year
- Massive hemoptysis history: Episodes requiring transfusion or bronchial artery embolization
- Chronic respiratory failure: Persistent hypoxemia requiring continuous oxygen
- Cor pulmonale: Right heart failure from chronic lung disease
- Multidrug-resistant organisms: Colonization with organisms requiring IV antibiotics
- Recurrent pneumothorax: Multiple collapsed lung episodes
- Uncontrolled comorbidities: Concurrent COPD, severe asthma, or immune deficiency
Pulmonary Function Tests and Their Critical Role
Key insight: FEV1 percentage predicted is the single most objective measure underwriters use to assess bronchiectasis severity and assign risk classifications.
Pulmonary function tests (PFTs) provide quantitative data about lung capacity and airflow, making them indispensable in underwriting respiratory diseases.
Key Pulmonary Function Metrics
| PFT Measurement | What It Measures | Underwriting Significance |
|---|---|---|
| FEV1 (Forced Expiratory Volume in 1 second) | Amount of air forcefully exhaled in first second | Very High – primary severity indicator |
| FVC (Forced Vital Capacity) | Total amount of air forcefully exhaled | High – helps identify restrictive patterns |
| FEV1/FVC Ratio | Proportion of lung capacity exhaled in first second | High – confirms obstructive pattern |
| DLCO (Diffusing Capacity) | Ability to transfer oxygen from lungs to blood | Moderate – indicates gas exchange impairment |
| Oxygen Saturation | Percentage of hemoglobin saturated with oxygen | High – identifies hypoxemia need for oxygen |
FEV1 and Rate Classifications
FEV1 percentage of predicted normal is directly correlated with insurance rate classifications:
FEV1 ≥80% Predicted
Disease Impact: Mild obstruction
Typical Rating: Standard to Table 2
Requirements: Low exacerbation rate, no complications
FEV1 70-79% Predicted
Disease Impact: Mild-moderate obstruction
Typical Rating: Table 2-4
Requirements: Stable trend, manageable exacerbations
FEV1 60-69% Predicted
Disease Impact: Moderate obstruction
Typical Rating: Table 4-6
Requirements: Careful carrier selection needed
FEV1 50-59% Predicted
Disease Impact: Moderate-severe obstruction
Typical Rating: Table 6-10
Requirements: Must show stability, limited carriers
FEV1 <50% Predicted
Disease Impact: Severe obstruction
Typical Rating: Often postponed or declined
Requirements: Consider alternative products
Serial PFTs: Demonstrating Stability
A single pulmonary function test provides a snapshot, but underwriters want to see trends over time:
✓ Optimal PFT Documentation Pattern
- Multiple tests over time: PFTs from at least 2-3 different dates spanning 12-24 months
- Stable values: FEV1 remaining within 5-10% of baseline (accounting for normal variability)
- No rapid decline: FEV1 loss of <3% per year indicates stable disease
- Consistent testing conditions: Tests performed with proper technique and reproducibility
- Recent testing: Most recent PFT within 6-12 months of application
- Post-bronchodilator values: Response to bronchodilators documented
⚠️ PFT Patterns That Concern Underwriters
- Progressive decline: FEV1 dropping 5%+ per year
- Severe obstruction: FEV1 <50% predicted even if stable
- Poor reversibility: Minimal response to bronchodilators
- Low DLCO: <50% predicted suggests significant gas exchange impairment
- Resting hypoxemia: Oxygen saturation <92% at rest
- Outdated testing: Most recent PFT more than 12-18 months old
Complications That Affect Insurability
Key insight: Bronchiectasis complications—particularly hemoptysis, respiratory failure, and cor pulmonale—dramatically worsen insurability and often result in postponement or decline.
Underwriters pay close attention to whether bronchiectasis has caused serious complications, as these indicate advanced disease and higher mortality risk.
Hemoptysis (Coughing Up Blood)
Blood in sputum is common in bronchiectasis but severity matters enormously:
- Mild hemoptysis (streaks of blood): Minor impact if infrequent. Documented as normal disease feature. May add Table 2 to base rating.
- Moderate hemoptysis (tablespoons of blood): Concerning if recurrent. Requires bronchoscopy evaluation. Adds Table 2-4 to base rating.
- Massive hemoptysis (>200-300 mL): Life-threatening complication. Often requires bronchial artery embolization or surgery. Results in postponement for 12-24 months, then Table 6-10 if stable.
Respiratory Failure
Acute or chronic respiratory failure indicates severe disease:
⚠️ Respiratory Failure Impact
- Acute respiratory failure episode: Requiring ICU admission and mechanical ventilation typically results in 12-24 month postponement, then very high table ratings
- Chronic respiratory failure: Persistent hypoxemia requiring continuous supplemental oxygen usually results in postponement or decline for traditional coverage
- Hypercapnia: Elevated CO2 levels indicating advanced disease and poor prognosis
- Non-invasive ventilation: Need for BiPAP or CPAP suggests severe nocturnal desaturation
Cor Pulmonale (Right Heart Failure)
Chronic lung disease causing right heart strain and failure:
- Development of cor pulmonale indicates advanced bronchiectasis with poor prognosis
- Symptoms include peripheral edema, elevated jugular venous pressure, hepatomegaly
- Diagnosed via echocardiogram showing right ventricular dysfunction and pulmonary hypertension
- Typically results in postponement or decline for traditional life insurance
- May qualify for guaranteed issue products only
Infectious Complications
Chronic bacterial colonization and resistant organisms affect underwriting:
| Organism | Clinical Significance | Underwriting Impact |
|---|---|---|
| Normal Flora / Commensal Bacteria | No pathogenic organisms | Minimal – best scenario |
| Haemophilus influenzae | Common bronchiectasis pathogen | Low – expected finding |
| Pseudomonas aeruginosa | Associated with more severe disease and faster decline | Moderate to High – adds table ratings |
| MRSA (Methicillin-Resistant Staph aureus) | Difficult to treat, requires IV antibiotics | High – significant concern |
| Non-Tuberculous Mycobacteria (NTM) | Chronic infection requiring prolonged treatment | Very High – often postponement |
| Aspergillus (ABPA) | Allergic reaction complicating disease | Moderate – depends on control |
Essential Medical Documentation
Key insight: Comprehensive pulmonary documentation demonstrating disease stability, controlled exacerbation rate, and maintained lung function is essential for any chance of approval.
Thorough, well-organized medical records significantly improve your underwriting outcome for bronchiectasis applications.
Required Documentation Checklist
Core Pulmonary Records
- Pulmonologist consultation notes: Complete records from diagnosis through most recent visit (past 3-5 years)
- Chest CT scan reports: High-resolution CT showing extent and distribution of bronchiectasis
- Serial pulmonary function tests: At least 2-3 PFTs over past 12-24 months showing trends
- Exacerbation history: Detailed documentation of all respiratory infections requiring treatment in past 2 years
- Hospital discharge summaries: All respiratory-related admissions with treatment details
- Sputum culture results: Recent cultures showing bacterial colonization status
- Medication list: Complete current respiratory medications with dosages
- Oxygen saturation monitoring: Resting and exertional oxygen levels
Supplemental Documentation That Strengthens Applications
- Pulmonologist summary letter: Current assessment of disease severity, stability, and prognosis
- Six-minute walk test: Objective measure of exercise tolerance and oxygen requirements
- Bronchoscopy reports: If performed to evaluate hemoptysis or other complications
- Genetic testing: If performed to identify underlying cause (cystic fibrosis, ciliary dysfunction)
- Immunology workup: If immune deficiency suspected as underlying cause
- Treatment adherence records: Evidence of airway clearance technique compliance
- Quality of life assessments: Functional status and activity level documentation
Optimal Documentation Timeline
📋 At Diagnosis
- Initial chest CT confirming bronchiectasis
- Baseline pulmonary function tests
- Workup for underlying cause
- Pulmonologist initial assessment
Monitoring Period (First 12 Months):
- Treatment plan implementation
- Documentation of exacerbation frequency and treatment responses
- Follow-up PFTs at 6-12 months
- Adjustment of management strategies
Optimal Application Window (12-24+ Months Post-Diagnosis):
- Established pattern of exacerbation frequency (ideally ≤2 per year)
- Serial PFTs showing stable lung function
- No hospitalizations in past 12-24 months
- Well-defined treatment regimen with good compliance
- Recent comprehensive pulmonary evaluation (within 6 months)
✓ Documentation Best Practices
- Quantify stability: Clearly document exacerbation rate per year with treatment details
- Show trends: Present serial PFTs in a table or graph showing stability over time
- Highlight favorable factors: If you have mild disease, no Pseudomonas, and FEV1 >70%, make this prominent
- Provide context: Explain any hospitalizations (was it 3 years ago? isolated event?)
- Update before applying: Ensure PFTs and pulmonologist visit within 6 months of application
- Organize chronologically: Clear timeline from diagnosis to current stable state
Best Carriers for Bronchiectasis Applicants
Key insight: Very few carriers will consider bronchiectasis cases, making expert carrier selection absolutely critical for approval and reasonable rates.
Bronchiectasis is classified as a high-risk pulmonary condition by most insurance companies. Carrier selection requires deep knowledge of which companies maintain appetite for chronic lung disease.
Carriers with Pulmonary Disease Experience
| Insurance Carrier | Bronchiectasis Underwriting Approach | Best For |
|---|---|---|
| Prudential | Will consider mild cases with comprehensive workup; sophisticated pulmonary underwriting | Mild bronchiectasis, FEV1 >70%, 0-1 exacerbations/year |
| Pacific Life | Risk-stratified approach for respiratory conditions; considers moderate cases | Moderate disease with stable PFTs and manageable exacerbations |
| Lincoln Financial | Willing to table-rate pulmonary conditions; detailed risk assessment | Well-documented cases willing to accept table ratings |
| Mutual of Omaha | May consider mild cases with clear stability documentation | Localized disease, minimal symptoms, strong PFTs |
| American General (AIG) | Substandard risk specialists; willing to issue higher table ratings | Moderate to severe cases needing table 6-10 options |
Our Top 10 Best Life Insurance Companies in the U.S. (2025): Expert Broker Rankings can help identify carriers most likely to provide favorable consideration for chronic pulmonary conditions.
Alternative Coverage Options
For moderate to severe bronchiectasis, traditional fully-underwritten policies may not be available. Consider these alternatives:
Simplified Issue Policies
Features:
- No medical exam required
- Health questionnaire only
- Faster approval (2-4 weeks)
- Coverage up to $250,000-$500,000
- Higher premiums than fully underwritten
Best For: Mild to moderate bronchiectasis with manageable symptoms
Guaranteed Issue Policies
Features:
- No health questions asked
- Immediate approval
- Graded death benefit (2-3 years)
- Coverage typically $5,000-$25,000
- Highest premiums per dollar
Best For: Severe bronchiectasis unable to qualify for traditional coverage
Group Life Insurance
Features:
- Guaranteed issue through employer
- No underwriting for base amount
- Immediate coverage
- Limited portability
- Coverage ends with employment
Best For: Any severity; immediate protection while pursuing individual coverage
Professional Insight
“Bronchiectasis applications require strategic carrier targeting. Of the major carriers, only a handful will even consider bronchiectasis cases, and among those, appetites vary dramatically based on severity. We’ve seen identical mild bronchiectasis profiles receive Standard Table 2 from one carrier and outright decline from another. Our approach involves pre-screening 3-4 targeted carriers based on the client’s specific severity profile before formal application. For moderate to severe cases, we often recommend a dual strategy: apply for traditional coverage with the most lenient carrier while simultaneously securing guaranteed issue coverage for immediate protection.”
– InsuranceBrokers USA – Management Team
Frequently Asked Questions
Can I get life insurance if I was just recently diagnosed with bronchiectasis?
Yes, but applying immediately after diagnosis typically results in postponement or unfavorable rates. Underwriters need to see an established pattern of disease severity, exacerbation frequency, and treatment response—information that only becomes clear over 12-24 months. If you apply within 6 months of diagnosis, most carriers will postpone your application asking you to reapply after establishing stability. The optimal approach is to wait at least 12 months after diagnosis, during which time you complete comprehensive pulmonary testing, establish a treatment regimen, and document your exacerbation rate. This patience can mean the difference between postponement and Standard Table 4 rates, potentially saving thousands of dollars over your policy lifetime. Use this waiting period strategically to optimize your disease control and compile thorough medical documentation.
Will having cystic fibrosis-related bronchiectasis automatically disqualify me from coverage?
Cystic fibrosis (CF) significantly complicates life insurance eligibility, even when bronchiectasis is the primary manifestation. CF carries substantial mortality risk with median survival now extending into the 40s due to improved treatments, but it remains a progressive, life-limiting disease. Most traditional life insurance carriers will decline CF cases or offer them only at prohibitively high table ratings (Table 10+). However, options exist: some specialty carriers may consider very mild CF with excellent pulmonary function (FEV1 >80%), minimal exacerbations, and no diabetes or other complications, typically offering Table 8-12. Guaranteed issue policies provide coverage without health questions, though with graded death benefits and higher premiums. Group life insurance through employers offers guaranteed issue coverage for the base amount. If you have CF-related bronchiectasis, working with a broker specializing in high-risk cases is essential to identify the few carriers willing to consider your application.
How do frequent antibiotic courses affect my life insurance application?
Antibiotic frequency directly correlates with exacerbation rate, which is one of the most critical underwriting factors. If you require oral antibiotics 3-4 times per year for respiratory exacerbations, underwriters view this as moderate disease severity, typically resulting in Table 4-6 ratings. If you need intravenous antibiotics multiple times yearly or are on continuous oral antibiotics as suppressive therapy, this indicates more severe disease and results in higher table ratings (Table 6-10) or possible postponement. The key is demonstrating that antibiotic courses are effectively controlling infections and that exacerbation frequency is stable or decreasing, not increasing. Document each antibiotic course with dates, indications, and responses. If you’ve been able to reduce antibiotic frequency through improved airway clearance or preventive strategies, highlight this positive trend. Underwriters distinguish between planned prophylactic antibiotics (rotating antibiotics to prevent infections) and reactive treatment of acute exacerbations—the former may be viewed less negatively if it successfully prevents hospitalizations.
What if my lung function is declining despite treatment?
Progressive decline in pulmonary function is one of the most concerning findings for underwriters and typically results in postponement or decline. If your FEV1 is dropping more than 3-5% per year, this suggests your bronchiectasis is not adequately controlled and predicts continued deterioration and shortened life expectancy. In this situation, the best strategy is to postpone your life insurance application and work intensively with your pulmonologist to stabilize your disease—this might involve more aggressive airway clearance, different antibiotic regimens, treatment of underlying causes like immune deficiency, or addressing comorbid conditions like GERD. Once you achieve 12-18 months of stable lung function (FEV1 not declining or even improving), you’ll have much better prospects for approval. Some decline is expected with aging, but the rate matters enormously. If your decline has stabilized at a slower rate, document this improvement trend prominently. For cases with established progressive decline despite optimal treatment, guaranteed issue policies may be the only viable option for immediate coverage needs.
Should I mention bronchiectasis if it’s very mild and rarely causes problems?
Yes, you absolutely must disclose it. Life insurance applications specifically ask about lung diseases and respiratory conditions, and bronchiectasis qualifies regardless of severity. Failing to disclose diagnosed bronchiectasis constitutes material misrepresentation and can result in claim denial or policy rescission even years later. Insurance companies will obtain your complete medical records during underwriting and will discover the bronchiectasis in chest CT reports, pulmonologist notes, or medication histories. Here’s the important perspective: if your bronchiectasis truly is mild with rare symptoms, excellent lung function, and minimal treatment needs, underwriters will likely view it favorably and you may qualify for Standard Table 2-4 rates. Attempting to hide it gains nothing since it will be discovered anyway, and creates additional problems by demonstrating dishonesty. Always disclose fully and let your favorable clinical picture (high FEV1, low exacerbation rate, no complications) speak for itself in determining your actual risk classification.
Can I get life insurance if I’ve been hospitalized for bronchiectasis exacerbations?
Yes, but hospitalization history significantly impacts your rates and may require waiting periods. A single hospitalization more than 2-3 years ago has moderate impact if followed by stability—you might qualify for Table 4-6. If you’ve had multiple hospitalizations (2-3) in the past two years, expect Table 6-10 or possible postponement. Three or more hospitalizations in the past year typically results in postponement for 12-24 months. The key factors underwriters evaluate include: time since last hospitalization (more than 12-24 months preferred), reason for admission (routine exacerbation vs. respiratory failure or massive hemoptysis), length of stay (short stays better than prolonged ICU admissions), treatment required (oral antibiotics vs. IV antibiotics vs. mechanical ventilation), and your trajectory since hospitalization (improved stability vs. ongoing frequent admissions). If your hospitalization pattern shows improvement—for example, three hospitalizations three years ago, one hospitalization two years ago, and none in the past 18 months—emphasize this positive trend. Consider waiting to apply until you’ve achieved maximum time since last hospitalization to secure better rates.
How does bronchiectasis combined with asthma or COPD affect my application?
Coexisting obstructive lung diseases compound underwriting complexity and generally worsen your risk classification. Bronchiectasis with asthma might be viewed somewhat less unfavorably than bronchiectasis with COPD, as asthma can be well-controlled and doesn’t necessarily imply progressive lung damage. However, both conditions together typically add at least 2-4 table ratings beyond what bronchiectasis alone would receive. Bronchiectasis with COPD is particularly challenging because both conditions are progressive and their combination accelerates lung function decline. Underwriters will evaluate: your combined FEV1 (must be at least 60% for any consideration), total exacerbation burden from both conditions, smoking history (current smoking usually results in decline), medication requirements for both diseases, and evidence of disease stability. The distinction between COPD-associated bronchiectasis (very common) and truly independent coexisting conditions matters. Emphasize any stability in lung function and low combined exacerbation rate. Expect Table 6-10 in most cases, with severe combined disease often resulting in postponement or decline.
What happens to my coverage if my bronchiectasis worsens after I’m approved?
Your premium is locked in at the rate determined when your policy was issued and cannot increase due to worsening of your bronchiectasis or any other health changes. This is a fundamental principle of life insurance—rates are based on your health at application and remain fixed for the policy duration, whether term or permanent. Even if your FEV1 declines, you develop complications like cor pulmonale, require continuous oxygen, or have frequent hospitalizations, your existing policy premiums stay the same. The only exceptions are: if you selected a term policy and try to renew it at the end of the term (renewal rates are based on age but are typically very expensive and generally not advisable), or if you apply for additional new coverage (which would be underwritten based on your current health). This underscores the importance of securing coverage when your disease is relatively stable and well-controlled—you lock in rates even if your condition deteriorates later. It also explains why carriers are so careful in initial underwriting, as they’re accepting risk that could worsen over decades without ability to adjust premiums.
Ready to Explore Life Insurance Options with Bronchiectasis?
Don’t let chronic lung disease concerns prevent you from protecting your family’s financial security. Our specialized team understands bronchiectasis underwriting and works with carriers willing to consider pulmonary conditions. Get a free, confidential consultation to discover your coverage options.
Free confidential consultation – All consultations are HIPAA compliant
